PF-00337210

PF-00337210 is a potent and highly selective small molecule inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase. It acts as an ATP-competitive inhibitor that selectively binds to VEGFR2 and prevents its phosphorylation. This inhibition disrupts downstream signaling pathways involved in the migration, proliferation, and survival of endothelial cells as well as microvessel formation (angiogenesis), ultimately leading to reduced tumor cell proliferation and potential tumor cell death. Originally developed for oncology indications such as advanced solid tumors, it has also been considered for ophthalmic diseases like age-related macular degeneration via intravitreal injection. The drug was developed by Pfizer[1][2][4][5][6].

Other names

N,2-Dimethyl-6-{[7-(2-morpholin-4-ylethoxy)quinolin-4-yl]oxy}-1-benzofuran-3-carboxamide854514-88-83K3KYC9LES